Affiliation:
1. Ryazan State Medical University
Abstract
One way to analyze the activity of the ABCB1 protein is to assess the accumulation of its substrate fexofenadine (F.) inside the test cells. The goal is to develop and validate a method for the quantitative analysis of F. in Caco-2 cell lysate using HPLC-MS/MS. Materials and methods. Caco-2 cell lysate was used as a matrix. The analysis was performed on an "Ultimate 3000" chromatograph with a TSQ Fortis triple quadrupole mass detector, a UCT Selectra C18 4.6 mm*100 mm 5 µm column in a gradient elution mode. The mobile phase rate was 0.3 ml/min, the sample volume was 20 µl, the ionization mode was positive, and the internal standard was amantadine (ng/ml). Sample preparation — precipitation of cell lysate protein with acetonitrile. The method was validated for the following parameters: selectivity, linearity, lower limit of quantitation (LLOQ), correctness, precision, sample transfer and sample stability. Results. Chromatograms of the blank lysate of Caco-2 cells showed no peaks with retention times characteristic of F. (5.70 min) and amantadine (3.58 min). NPKO F. was 0.5 ng/ml. F.'s transfer did not exceed 20% of NPKO, and amantadine — 5%. Based on the results of the analysis of three series of calibration standards (0.5; 1; 1.5; 5; 10; 25; 40; 50 ng/ml), linear regression equations were obtained, the correlation coefficients exceeded 0.99. Accuracy and precision were assessed within and between cycles by analyzing F. solutions in the matrix (0.5; 1.5; 25 and 40 ng/ml) within three cycles. The parameters did not exceed 20% for LLPO and 15% for other points. The stability of F. solutions (1.5 and 40 ng/ml) in the lysate was analyzed during storage at room temperature, after 3-fold freezing-thawing, storage at -80 °C for 60 days, after sample preparation and being in the autosampler for 24 hours. The accuracy was within 15% of the nominal values. Conclusions. A method for the quantitative determination of F. in Caco-2 cell lysate using HPLC-MS/MS has been developed and validated.
Subject
Pharmacology (medical),Complementary and alternative medicine,Pharmaceutical Science
Reference14 articles.
1. Spudich A, Kilic E, Xing H, et al. Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia. Nat Neurosci. 2006 Apr;9(4):487–8. DOI: 10.1038/nn1676.
2. Chernykh I.V., Shchul'kin A.V., Yakusheva E.N., Popova N.M. Rol' glikoproteina-R v nevrologii. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2017;117(1):67–71. [Chernykh IV, Shchulkin AV, Yakusheva EN, Popova NM. A role of P-glycoprotein in neurology. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2017;117(1):67–71. (In Russ).]. DOI: 10.17116/jnevro20171171167-71.
3. Sychev D.A., Kukes V.G., Karkishchenko N.N. Metodicheskie rekomendatsii po izucheniyu biotransformatsii i transporterov novykh lekarstvennykh sredstv: dizain issledovanii, analiz dannykh: rukovodstvo po ekspertize lekarstvennykh sredstv. M.: Grif i K; 2014. [Sychev DA, Kukes VG, Karkishhenko NN. Metodicheskie rekomendacii po izucheniyu biotransformacii i transporterov novy`x lekarstvenny`x sredstv: dizajn issledovanij, analiz danny`x: rukovodstvo po e`kspertize lekarstvenny`x sredstv. Moscow: Grif i K; 2014. (In Russ).].
4. Clinical Drug Interaction Studies — Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Clinical Pharmacology. (2020).
5. In Vitro Drug Interaction Studies — Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Clinical Pharmacology. (2020).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献